Salmi HA, Sarna S. Effect of silymarin on
chemical, functional and morphological alterations of the liver. A double-blind
controlled study.
Scand J Gastroenterol.
1982;17:517-521.
Feher J, Desk G, Muzes G,
et al. Liver protective action of silymarin therapy in chronic alcoholic liver
diseases [in Hungarian].
Orv Hetil.
1989;130:2723-2727.
Fintelmann V, Albert A.
Proof of the therapeutic efficacy of LegalonW for toxic liver illnesses in a
double-blind trial [translated from German].
Therapiewoche.
1980;30:5589-5594.
Trinchet JC, Coste T, Levy VG, et al. Treatment of alcoholic
hepatitis with silymarin. A double-blind comparative study in 116 patients
[translated from French].
Gastroenterol Clin Biol.
1989;13:120-124.
Bunout D,
Hirsch SB, Petermann MT, et al. Controlled study of the effect of silymarin on
alcoholic liver disease [translated from Spanish].
Rev Med
Chil.
1992;120:1370-1375.
McClain CJ, Hill DB, Song Z, et al.
S-Adenosylmethionine, cytokines, and alcoholic liver disease.
Alcohol.
2002;27:185-192.
Abittan CS, Lieber CS. Alcoholic liver
disease.
Curr Treat Options Gastroenterol.
1999;2:72-80.
Rambaldi A, Gluud C.
S-adenosyl-L-methionine for alcoholic liver diseases.
Cochrane Database
Syst Rev. 2001;CD002235.
Lieber CS, Casini A, DeCarli LM, et al.
S-adenosyl-L-methionine attenuates alcohol-induced liver injury in the baboon.
Hepatology.
1990;11:165-172.
Barak AJ, Beckenhauer HC, Tuma DJ.
Betaine, ethanol and the liver: a review.
Alcohol.
1996;13:395-398.
Barak
AJ, Beckenhauer HC, Junnila M, et al. Dietary betaine promotes generation of
hepatic S-adenosylmethionine and protects the liver from ethanol-induced fatty
infiltration.
Alcohol Clin Exp Res.
1993;17:552-555.
Murakami T, Nagamura Y,
Hirano K. The recovering effect of betaine on carbon tetrachloride-induced
liver injury.
J Nutr Sci Vitaminol.
1998;44:249-255.
Kanbak G, Inal M, Baycu
C. Ethanol-induced hepatotoxicity and protective effect of betaine.
Cell Biochem Funct.
2001;19:281-285.
Leo MA, Lieber CS. Alcohol, vitamin A,
and beta-carotene: adverse interactions, including hepatotoxicity and
carcinogenicity.
Am J Clin Nutr.
1999;69:1071-1085.
Ni R, Leo MA, Zhao J,
Lieber CS. Toxicity of beta-carotene and its exacerbation by acetaldehyde in
HepG2 cells.
Alcohol.
2001;36:281-285.
Veh I, Chatterjee SS, Kiianmaa K, et al.
Reduction of voluntary ethanol intake in alcohol-preferring AA-rats by kava
extract. Presented at International Congress and 49th Meeting of the Society
for Medicinal Plant Research; September 2-6, 2001; Erlangen, Germany.
Rambaldi A, Jacobs B, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases.
Cochrane Database Syst Rev.
2007;CD003620.
Saller R, Brignoli R, Melzer J, et al. An updated systematic review with meta-analysis for the clinical evidence of silymarin.
Forsch Komplement Med.
2008;15:9-20.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.